Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapoxetine in Rapid Ejaculation
NCT00211094Phase 3Completed
- Sponsor
- ALZA Corporation
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of dapoxetine in premature ejaculation (PE) (3 arms), sponsored by ALZA Corporation. Primary endpoint: Average Intravaginal Ejaculatory Latency Time at 12 weeks. Status: completed.
02
Drugs
dapoxetine
03
Conditions
premature ejaculation (PE)
Beyond the preview
Go deeper on NCT00211094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00211094.